Unlike Aduhelm at least Relyvrio doesn't cause heavy side effects like brain bleed and has shown some effectiveness. It's mechanism of action also makes some sense. It consists of two drugs one of which removes excess nitrogen which would lower reactive oxygen species (ROS) in turn lessening inflammation and cell damage. The other drug reduces cytochrome c and caspases to reduce mitochondrial injury.

A.L.S. for which it's approved is also on our disease list. Leronlimab also reduces ROS and downregulates cytochrome c, caspase 1, 3 and 9 (possibly others) and has other mechanisms to lower inflammation, cell damage and mitochondrial damage. Given the broader range of action I think leronlimab would be far superior.

It would be nice to at least have mouse studies in A.L.S. and some other diseases just as proof of concept.